Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer

Oncology ◽  
2005 ◽  
Vol 68 (4-6) ◽  
pp. 485-492 ◽  
Author(s):  
Tony S.K. Mok ◽  
Kwok Chi Lam ◽  
Conrad Lee ◽  
Li Zhang ◽  
Herman Wong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Oral Etoposide ◽  
Toxicity Profile ◽  
Small Cell Lung

A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly

2006 ◽  
Vol 1 (2) ◽  
pp. 141-145 ◽  
Author(s):  
Yuh-Min Chen ◽  
Reury-Perng Perng ◽  
Chun-Ming Tsai ◽  
Jacqueline Whang-Peng
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
The Elderly ◽  
Small Cell ◽  
Small Cell Lung

Phase II trial with weekly cisplatin (CDDP) and continously oral etoposide (VP-16) in advanced non-small cell lung cancer (NSCLC)

1993 ◽  
Vol 29 ◽  
pp. S162
Author(s):  
R. Lopez ◽  
R. Fernandez ◽  
J.A. Virizuela ◽  
J. Cueva ◽  
E. Garcia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Oral Etoposide ◽  
Small Cell Lung ◽  
Weekly Cisplatin

A phase ii study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage iii non-small-cell lung cancer

1999 ◽  
Vol 44 (2) ◽  
pp. 343-348 ◽  
Author(s):  
Branislav Jeremic ◽  
Yuta Shibamoto ◽  
Biljana Milicic ◽  
Slobodan Milisavljevic ◽  
Nebojsa Nikolic ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Oral Etoposide ◽  
Small Cell Lung ◽  
Hyperfractionated Radiotherapy

A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7095-7095 ◽  
Author(s):  
A. Mueller ◽  
N. Thatcher ◽  
C. Kortsik ◽  
G. Koschel ◽  
W. Spengler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Study Results

A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7095-7095
Author(s):  
A. Mueller ◽  
N. Thatcher ◽  
C. Kortsik ◽  
G. Koschel ◽  
W. Spengler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Study Results

scholarly journals A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

2010 ◽  
Vol 5 (10) ◽  
pp. 1630-1636 ◽  
Author(s):  
John D. Hainsworth ◽  
Cristina L. Cebotaru ◽  
Vladimir Kanarev ◽  
Tudor E. Ciuleanu ◽  
Danail Damyanov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Open Label

scholarly journals A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer

2014 ◽  
Vol 25 (11) ◽  
pp. 2156-2162 ◽  
Author(s):  
S. Novello ◽  
B. Besse ◽  
E. Felip ◽  
F. Barlesi ◽  
J. Mazieres ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document